Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with premature mortality, severe morbidity, and functional impairment leading to considerable financial burden for both patients and society. Since disease progression and complications can differ from one patient to another, genetic markers are of potential relevance for identifying those individuals at a higher risk of more severe disease. RA is a complex polygenic disease. Cardiovascular (CV) disease due to accelerated atherogenesis is the most common cause of premature mortality in patients with RA. Several studies support the implication of genetic factors in the development of CV disease in RA. In addition to the strong association between alleles of the HLA-DRB1*04 shared epitope and both subclinical and clinically evident CV disease, genes implicated in inflammation and metabolism, such as TNFA, MTHFR, and CCR5, seem to be associated with a higher risk of CV disease in patients with RA. We propose the use of these genetic variants as molecular biomarkers that could help to predict disease outcome at diagnosis of RA and, therefore, to optimize the treatment and management of other risk factors from an early stage of the disease.
Keywords: Rheumatoid arthritis, outcome, polymorphism, cardiovascular disease.
Current Pharmaceutical Design
Title:Rheumatoid Arthritis: Genetic Variants as Biomarkers of Cardiovascular Disease
Volume: 21 Issue: 2
Author(s): Luis Rodriguez-Rodriguez, Raquel López-Mejias, Benjamín Fernández-Gutiérrez, Alejandro Balsa, Miguel A. González-Gay and Javier Martín
Affiliation:
Keywords: Rheumatoid arthritis, outcome, polymorphism, cardiovascular disease.
Abstract: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with premature mortality, severe morbidity, and functional impairment leading to considerable financial burden for both patients and society. Since disease progression and complications can differ from one patient to another, genetic markers are of potential relevance for identifying those individuals at a higher risk of more severe disease. RA is a complex polygenic disease. Cardiovascular (CV) disease due to accelerated atherogenesis is the most common cause of premature mortality in patients with RA. Several studies support the implication of genetic factors in the development of CV disease in RA. In addition to the strong association between alleles of the HLA-DRB1*04 shared epitope and both subclinical and clinically evident CV disease, genes implicated in inflammation and metabolism, such as TNFA, MTHFR, and CCR5, seem to be associated with a higher risk of CV disease in patients with RA. We propose the use of these genetic variants as molecular biomarkers that could help to predict disease outcome at diagnosis of RA and, therefore, to optimize the treatment and management of other risk factors from an early stage of the disease.
Export Options
About this article
Cite this article as:
Rodriguez-Rodriguez Luis, López-Mejias Raquel, Fernández-Gutiérrez Benjamín, Balsa Alejandro, A. González-Gay Miguel and Martín Javier, Rheumatoid Arthritis: Genetic Variants as Biomarkers of Cardiovascular Disease, Current Pharmaceutical Design 2015; 21 (2) . https://dx.doi.org/10.2174/1381612820666140825123407
DOI https://dx.doi.org/10.2174/1381612820666140825123407 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dry Eyes in Rheumatic Disease
Current Rheumatology Reviews Tacrolimus Treatment in Myasthenia Gravis
Current Drug Therapy Novel Coupled Molecules from Active Structural Motifs of Synthetic and Natural Origin as Immunosuppressants
Medicinal Chemistry Cot/Tpl-2 Protein Kinase as a Target for the Treatment of Inflammatory Disease
Current Topics in Medicinal Chemistry The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism Interferon-beta Inhibits Th17 Cell Differentiation in Patients with Multiple Sclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Implications of Superoxide Dismutase And Its Importance in Kinase Drug Discovery
Current Topics in Medicinal Chemistry Potential Factors Induced by Filoviruses that Lead to Immune Supression
Current Molecular Medicine Subject Index to Volume 5
Current Drug Metabolism The Brain-Immune-Gut Triangle: Innate Immunity in Psychiatric and Neurological Disorders
Current Immunology Reviews (Discontinued) Innate Immune System Modulation During Aging: Contributions of Macrophages and Dendritic Cells
Current Immunology Reviews (Discontinued) The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Comparison of Large Proteomic Datasets
Current Proteomics Uveitis in Horses, Rats and Man: What Do We Learn from Our Pets?
Current Immunology Reviews (Discontinued) The Role of HLA-B27 in the Pathogenesis of Ankylosing Spondylitis
Current Rheumatology Reviews Glucocorticoids in Pregnancy
Current Pharmaceutical Biotechnology Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Chemokines in Rheumatic Diseases
Current Drug Targets Editorial [Hot Topic: Bone and Immune System Cross-Talk (Guest Editors: Nadia Rucci and Hiroshi Takayanagi)]
Inflammation & Allergy - Drug Targets (Discontinued)